# YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT05913804** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** YTS104 Cells injection

## Key facts

- **NCT ID:** NCT05913804
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-28
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913804, "YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05913804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*